Patents by Inventor Pavel Strop
Pavel Strop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170313787Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.Type: ApplicationFiled: May 11, 2017Publication date: November 2, 2017Applicants: PFIZER INC., RINAT NEUROSCIENCE CORP.Inventors: Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David SHELTON, Shu-Hui LIU, Jaume PONS, Russell DUSHIN
-
Patent number: 9676871Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.Type: GrantFiled: November 3, 2011Date of Patent: June 13, 2017Assignees: PFIZER INC., RINAT NEUROSCIENCE CORP.Inventors: Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Shelton, Shu-Hui Liu, Jaume Pons, Russell Dushin
-
Publication number: 20170151341Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.Type: ApplicationFiled: November 21, 2016Publication date: June 1, 2017Applicant: Pfizer Inc.Inventors: Dangshe MA, Frank LOGANZO, JR., Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Pavel STROP
-
Publication number: 20170058054Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglubulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.Type: ApplicationFiled: November 14, 2016Publication date: March 2, 2017Applicant: RINAT NEUROSCIENCE CORP.Inventors: Weihsien HO, Jaume PONS, Arvind RAJPAL, Pavel STROP
-
Publication number: 20170043033Abstract: The present invention provides transglutaminase-mediated antibody-drug conjugates with high anti-body-drug ratio (DAR) comprising 1) glutamine-containing tags, endogenous glutamines, and/or endogenous glutamines made reactive by antibody engineering or an engineered transglutaminase (e.g., with altered substrate specifity); and 2) amine donor agents comprising amine donor units, linkers, and agent moieties, wherein the DAR is at least about 5. The invention also provides methods of making and methods of using such higher drug loaded antibody-drug conjugates.Type: ApplicationFiled: April 21, 2015Publication date: February 16, 2017Applicants: RINAT NEUROSCIENCE CORP., PFIZER INC.Inventors: Pavel STROP, Katherine Anne DELARIA, Magdalena DORYWALSKA, Davide Luciano FOLETTI, Russell George DUSHIN, David Louis SHELTON, Arvind RAJPAL
-
Patent number: 9527926Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.Type: GrantFiled: May 13, 2011Date of Patent: December 27, 2016Assignee: RINAT NEUROSCIENCE CORP.Inventors: Wei-Hsien Ho, Jaume Pons, Arvind Rajpal, Pavel Strop
-
Publication number: 20160297885Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.Type: ApplicationFiled: March 30, 2016Publication date: October 13, 2016Applicant: PFIZER INC.Inventors: Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
-
Publication number: 20160257746Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: ApplicationFiled: May 20, 2016Publication date: September 8, 2016Inventors: Shu-Hui LIU, Wei-Hsien HO, Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David Louis SHELTON, Thomas-Toan TRAN
-
Patent number: 9399074Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: GrantFiled: August 15, 2014Date of Patent: July 26, 2016Assignee: Rinat Neuroscience Corp.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Publication number: 20160193356Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates) comprising specific acyl donor glutamine-containing tags and amine donor agents. The invention also provides methods of making such engineered polypeptide conjugates using transglutaminase and methods of using thereof.Type: ApplicationFiled: July 30, 2014Publication date: July 7, 2016Applicant: RINAT NEUROSCIENCE CORP.Inventors: Santiago Esteban FARIAS, Meritxell GALINDO CASAS, Pavel STROP
-
Publication number: 20160096898Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.Type: ApplicationFiled: September 24, 2015Publication date: April 7, 2016Applicants: PFIZER INC., RINAT NEUROSCIENCE CORP.Inventors: Hong LIANG, Yasmina Noubia ABDICHE, Javier Fernando CHAPARRO RIGGERS, Bruce Charles GOMES, Julie Jia Li HAWKINS, Jaume PONS, Xiayang QIU, Pavel STROP, Yuli WANG
-
Patent number: 9249186Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.Type: GrantFiled: July 8, 2015Date of Patent: February 2, 2016Assignee: Pfizer Inc.Inventors: Matthew David Doroski, Andreas Maderna, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell George Dushin, Pavel Strop, Edmund Idris Graziani
-
Patent number: 9175093Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.Type: GrantFiled: April 4, 2013Date of Patent: November 3, 2015Assignees: RINAT NEUROSCIENCE CORP., PFIZER INC.Inventors: Hong Liang, Yasmina Noubia Abdiche, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Julie Jia Li Hawkins, Jaume Pons, Xiayang Qiu, Pavel Strop, Yuli Wang
-
Publication number: 20150307551Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.Type: ApplicationFiled: July 8, 2015Publication date: October 29, 2015Inventors: Matthew David DOROSKI, Andreas MADERNA, Christopher John O'DONNELL, Chakrapani SUBRAMANYAM, Beth VETELINO, Russell George DUSHIN, Pavel STROP, Edmund Idris GRAZIANI
-
Patent number: 9138486Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.Type: GrantFiled: July 2, 2014Date of Patent: September 22, 2015Assignee: Pfizer Inc.Inventors: Matthew David Doroski, Andreas Maderna, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell George Dushin, Pavel Strop, Edmund Idris Graziani
-
Publication number: 20140363452Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.Type: ApplicationFiled: July 2, 2014Publication date: December 11, 2014Inventors: Matthew David DOROSKI, Andreas MADERNA, Christopher John O'DONNELL, Chakrapani SUBRAMANYAM, Beth VETELINO, Russell George DUSHIN, Pavel STROP, Edmund Idris GRAZIANI
-
Publication number: 20140357844Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: ApplicationFiled: August 15, 2014Publication date: December 4, 2014Inventors: Shu-Hui LIU, Wei-Hsien HO, Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David Louis SHELTON, Thomas-Toan TRAN
-
Patent number: 8871908Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: GrantFiled: November 7, 2012Date of Patent: October 28, 2014Assignee: Rinat Neuroscience Corp.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Patent number: 8828401Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.Type: GrantFiled: November 7, 2012Date of Patent: September 9, 2014Assignee: Pfizer Inc.Inventors: Matthew David Doroski, Andreas Maderna, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell George Dushin, Pavel Strop, Edmund Idris Graziani
-
Patent number: 8715673Abstract: The present invention provides antagonizing antibodies that bind to S. aureus alpha-toxin. The invention further provides a method of obtaining such antibodies and antibody encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies for the treatment and/or prevention of staphylococcal disease, including, for example, pneumonia, bacteremia, sepsis, eye infection, and abscess.Type: GrantFiled: December 18, 2012Date of Patent: May 6, 2014Assignee: Rinat Neuroscience Corp.Inventors: Davide Luciano Foletti, Javier Fernando Chaparro Riggers, Jacob Eli Gunn Glanville, Lee Mary Beth Shaughnessy, David Louis Shelton, Pavel Strop, Wenwu Zhai